SCHEMBL2731241

SCHEMBL2731241

c1ccc2c(c1)NCc1cccn1-2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRPF1 P55201 1/20 0.44
PTPN1 P18031 2/20 0.42
SIRT6 Q8N6T7 4/20 0.40
TSHR P16473 2/20 0.40
MAPK1 P28482 2/20 0.40
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
HPGD P15428 1/20 0.40
CASP1 P29466 1/20 0.40
CASP7 P55210 1/20 0.40
HSD17B3 P37058 1/20 0.38
ALOX15 P16050 1/20 0.34
HSD17B10 Q99714 1/20 0.34
GAA P10253 3/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
MAPT P10636 1/20 0.34
OPRM1 P35372 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30963678 1.00 BRPF1 (0.44) BRPF1PTPN1SIRT6TSHRMAPK1
SCHEMBL5738230 0.81 BRD4 (0.43) BRPF1PTPN1SIRT6TSHRMAPK1
SCHEMBL7315748 0.75 KDM4E (0.39) BRPF1TSHRMAPK1KDM4EALDH1A1
SCHEMBL13775962 0.75 BRPF1 (0.47) BRPF1PTPN1HSD17B3ALOX15HSD17B10
SCHEMBL5739134 0.73 SIRT6 (0.34) SIRT6
SCHEMBL9375733 0.73 BRPF1 (0.45) BRPF1PTPN1SIRT6TSHRMAPK1
SCHEMBL3458513 0.72 SMN1; SMN2 (0.46) PTPN1TSHRMAPK1L3MBTL1HSD17B10
SCHEMBL4990337 0.72 AHR (0.46) PTPN1KDM4EALDH1A1MEN1KMT2A
SCHEMBL15231171 0.71
SCHEMBL14511561 0.70 BRPF1 (0.42) BRPF1PTPN1SIRT6TSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118221684-A Method for preparing quinoxaline derivative through HFIP-promoted defluorination cyclization reaction of difluoro carbene reagent 陕西科技大学 2024-06-21 CN disclosed
CN-109400611-B Synthesis method of 1-vinyl-4, 5-dihydropyrrole [1,2-a ] quinoxaline compound 南京林业大学 2021-08-24 CN disclosed
US-20200061072-A1 COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION CERENIS THERAPEUTICS HOLDING SA (FR) 2020-02-27 US disclosed
US-10220040-B2 Compounds, compositions and methods useful for cholesterol mobilization CERENIS THERAPEUTICS HOLDING SA (FR) 2019-03-05 US disclosed
CN-106167483-B It can be used for compound, composition and the method for cholesterol mobilization 塞伦尼斯医疗控股有限公司 2019-02-15 CN disclosed
US-20180064718-A1 COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION ABIONYX PHARMA (FR) 2018-03-08 US disclosed
EP-3241833-A1 COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILISATION Cerenis Therapeutics Holding SA (FR) 2017-11-08 EP disclosed
US-9757381-B2 Compounds, compositions and methods useful for cholesterol mobilization CERENIS THERAPEUTICS HOLDING SA (FR) 2017-09-12 US disclosed
CN-107011359-A Compound, composition and the method mobilized available for cholesterol 塞伦尼斯医疗控股有限公司 2017-08-04 CN disclosed
US-9713619-B2 Compounds, compositions and methods useful for cholesterol mobilization CERENIS THERAPEUTICS HOLDING SA (FR) 2017-07-25 US disclosed
US-5624923-A UROGENITAL AND CARDIOVASCULAR DISORDERS AMERICAN CYANAMID COMPANY (US) 1997-04-29 US disclosed
US-5612334-A Tricyclic benzazepine vasopressin antagonists AMERICAN CYANAMID COMPANY (US) 1997-03-18 US disclosed
US-5610156-A USED IN TREATING DISEASES CHARACTERIZED BY EXCESS RENAL REABSORPTION OF WATER AMERICAN CYANAMID COMPANY (US) 1997-03-11 US disclosed
WO-1996022293-A1 TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS AMERICAN CYANAMID COMPANY (US) 1996-07-25 WO disclosed
WO-1996022292-A1 TRICYCLIC VASOPRESSIN ANTAGONISTS AMERICAN CYANAMID COMPANY (US) 1996-07-25 WO disclosed
US-5536718-A Tricyclic benzazepine vasopressin antagonists AMERICAN CYANAMID COMPANY (US) 1996-07-16 US disclosed
US-5521173-A TREATING DISEASES CHARACTERIZED BY EXCESS RENAL REABSORPTION OF WATER AMERICAN HOME PRODUCTS CORPORATION (US) 1996-05-28 US disclosed
US-5516774-A TREATING DISEASES CHARACTERIZED BY EXCESS RENAL REABSORPTION OF WATER AMERICAN CYANAMID COMPANY (US) 1996-05-14 US disclosed
CN-1106812-A Tricyclic diaza * vasopressin antagonists and oxytocin antagonists AMERICAN CYANAMID CO (US) 1995-08-16 CN disclosed
EP-0636625-A2 Tricyclic diazepine vasopressin antagonists and oxytocin antagonists AMERICAN CYANAMID COMPANY (US) 1995-02-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180064718-A1 COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION CETP, LIPA, NPC1L1 BRPF1 2230/4885PTPN1 3424/4885SIRT6 1084/4885
US-10220040-B2 Compounds, compositions and methods useful for cholesterol mobilization CETP, LIPA, NPC1L1 BRPF1 2230/4885PTPN1 3424/4885SIRT6 1084/4885
US-20200061072-A1 COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION CETP, LIPA, NPC1L1 BRPF1 2230/4885PTPN1 3424/4885SIRT6 1084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.